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Abstract  
Introduction: Designing and developing drug delivery systems has 
received tremendous attention during the last decade. The treatment of 
cancer cells is a complicated process due to the existence of different 
biological pathways. Therefore, the co-delivery of different drugs could 
have a synergic effect on the treatment process. 
Materials and Methods: In this study, different types of span (20, 60, 80) 
and cholesterol were utilized to formulate tamoxifen/curcumin co-loaded 
niosomes as a drug carrier system for breast cancer chemotherapy. 
Niosome characterization was performed through a set of instrument 
analysis techniques including scanning electron microscopy (SEM) and 
dynamic light scattering. Release behavior was studied by dialysis method 
at (pH = 5, 7.4). The stability was monitored during two months storage at 
two temperatures (4 and 25 °C). Cytotoxicity activity of the best niosomal 
formulation were assessed on MCF-7 cells, using MTT assay. 
Results: The optimal niosomal formulation with span 80 and lipid-to-drug 
molar ratio of 20 was selected, with maximum encapsulation of both drugs 
and minimum size. Drug release behavior at physiological pH (7.4) (with 
significant drug release under acidic conditions (pH = 5) and storage 
stability of up to 2 weeks with little change in drug efficacy and 
measurement makes it a proper candidate for breast cancer treatment.  
Conclusion: Finally, the results of this study showed the importance of 
creating highly biocompatible formulations, allowing the simultaneous 
transfer of two drugs with controlled release to cancer cells which could 
improve the chemotherapy process with the synergistic effect of the two 
drugs. 
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     Nano-carrier-based DDSs (drug delivery 
systems) work efficiently on malignant sites 
in chemotherapy. Encapsulating 
chemotherapy drugs using a nanoscale 
device is the best way to reduce the side 
effects and improve the availability of drugs 
for cancer. Nanoparticles have some 
advantages over the free drug, including 
improved drug delivery and release and 
improved drug stability in biological 
environments [1]. 
One of the most widely used nanoparticles 
are niosomes. Self-aggregated non-ionic 
amphiphiles in aqueous media form two-
layered structures called niosomes[2]. 
Niosomes have unique structures and can 
encapsulate hydrophilic and hydrophobic 
materials[3]. 
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Cancer has long been considered an 
incurable disease, and its prevention, 
diagnosis, and treatment are among serious 
and perennial challenges in medicine [1]. 
Each of the cancer treatment approaches 
have a number of undesirable side effects 
that are dangerous to the health of the 
patient. In contrast, recent advances in 
nanotechnology have dramatically reduced 
these side effects and raised hopes for 
effective and safe treatments [4].  
Breast cancer is a heterogeneous disease 
and is the most common malignancy in 
women  [5]. It is estimated that about every 
18 seconds a case of breast cancer is 
diagnosed and has a high mortality rate. 
Different classes of therapeutic agents and 
methods are used to treat breast cancer. 
Chemotherapy is one of the therapeutic 
methods that can be more effective if two or 
more drugs are used concurrently[6]. 
Curcumin (Cur) is a water and ether 
insoluble polyphenol and has antioxidant 
properties at acidic and neutral pHs. Its 
mechanism of action involves the inhibition 
of several cellular signaling pathways at 
multiple stages, with the effect on cellular 
enzymes such as cyclooxygenase and 
glutathione-s transferase, and the effect on 
angiogenesis and cell adhesion to each other 
which makes it is suitable for chemical 
treatment [7]. Tamoxifen (Tmx) is also 
widely used as a non-steroidal estrogen 
receptor antagonist and adjuvant drug for 
the treatment of breast cancer [8].  
This study aimed to investigate the role of 
nano-carriers in drug delivery to breast 
cancer cells and evaluate the synergistic 









2. Materials and Methods 
2.1 Reagents  
     Cholesterol, Span80, Span60, Span20, 
Sodium dodecyl sulfate (SDS) and Dialysis 
membrane (MWCO 12kDa) were bought 
from Sigma Aldrich (USA). Tmx and Cur 
drugs were provided by Iran Hormone and 
Exir Nano Sina companies (Iran) 
respectively. Chloroform, Amicon (Ultra-
15-Membrane, MWCO 30kDa) and 
Dimethyl sulfoxide (DMSO) were 
purchased from Merck (Germany). Medium 
RPMI-1640, DMEM (Dulbecco's Modified 
Eagle Medium), Trypsin-EDTA, Trypan 
blue, Fetal Bovine Serum (FBS), 
Phosphate-buffered saline (PBS), MTT 
(dimethylthiazol-2-yl-)-2,5, and Penicillin / 
Streptomycin (PS)100 X were taken from 
Gibco, (USA). HEK-293 and MCF-7 cell 
lines were obtained from Pasteur Cell Bank 
(Iran).  
 
2.2 Niosome Preparation  
     Loading of Tmx and Cur in the niosomes 
was performed by thin-layer hydration 
method; the details of this method is 
presented in previous work [9]. Briefly, 
cholesterol, surfactants, and drugs were 
dissolved in chloroform and chloroform 
evaporation was performed using a rotary 
evaporator (60 ° C, 30 min). Then, PBS was 
used to hydrate dry thin films at 60 ° C (30 
min). In order to co-load Tmx / Cur in the 
niosomes with uniform size distribution, the 
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2:1 7 1-1 10 Span20 TC1 Tmx/Cur 
(TC) 2:1 7 1-1 10 Span60 TC2 
2:1 7 1-1 10 Span80 TC3 
2:1 7 1-1 20 Span20 TC4 
2:1 7 1-1 20 Span60 TC5 
2:1 7 1-1 20 Span80 TC6 
a
 Lipid is the total amount of cholesterol and surfactant. 
 
2.3 Morphology 
     To investigate the morphology of the 
optimum formulation, SEM was used 
(NOVA NANOSEM 450 FEI, USA).  
 
2.4 Size and Polydispersity of Index 
Measurements 
     Malvern Zeta Sizer (Malvern Instrument, 
UK) was used to distribute the size and 
polydispersity index based on dynamic light 
scattering. 
 
2.5 Determination of Encapsulation 
Efficiency (EE) 
     The niosomes were ultra-filtered for 20 
min at 4000×g, utilizing an Amicon. 
Throughout filtration, free drugs passed 
through the filter membrane and the drug-
loaded niosomes remained in the top 
chamber. Drug concentration at a 
wavelength of maximum absorbance peak 
of each drug molecule was analyzed by UV 
visible spectroscopy (JASCO, V-530, 
Japan) (420 nm and 236 nm for Cur and 
Tmx) and drugs concentration was 
evaluated according to its standard curve. 
Finally, the encapsulation efficiency was 
computed using the following equation: 
 
Encapsulation Efficiency (%) 
=                       
                                                           
In this equation, A represents the amount of 
initial drug trapped into the niosomal 
formulations and B is the amount of free 
drug released from the membrane. 
 
2.6 In Vitro Drugs Release Kinetic 
Study 
     The in vitro Tmx/ Cur release from 
niosomes was studied through the following 
method. Briefly, 2 ml of each sample was 
added to a dialysis bag. The dialysis bag 
containing each sample was put in PBS-
SDS (0.5%, w/v) solution (pH = 5, 7.4) and 
stirred at 37 °C (50rpm). Then Aliquots 
were then taken at specified intervals and 
replaced with fresh medium. Different 
kinetic models were utilized to investigate 
and analyze the release profile. 
 
2.7 Niosome Stability studies  
     By measuring the average size, PDI and 
EE of the niosomes while storing the 
samples at 25 ° C and 4 ° C for two months, 
the stability of the samples was evaluated. 
 
2.8 In vitro Cytotoxicity Assay (MTT) 
     Cytotoxicity of samples in both HEK-
293 cell lines and MCF-7 cell lines using 
MTT assay was investigated. For this 
purpose, the cells were cultured and seeded 
into 96-well plates (10
4
 cells/well) utilizing 
RPMI-1640 as a medium that containing 
1% PS (1%) and FBS, 10%, and then 
incubated under 5% CO2 atmosphere 
(T=37°C, 24 h). Subsequently, different 
concentrations of the sample were added to 
the cell lines and incubated for 72 h. Then, 
each well medium was replaced by MTT 
(20 μL, 5 mg/mL) and was incubated for 4h 
in a 5% CO2 atmosphere (T=37°C). The 
supernatant was eliminated and 100 μl of 
isopropanol was added to dissolve the 
formazan crystals generated by the living 
cells. Finally, MTT absorbance was 
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measured at 570 nm, using an ELISA 
Reader (Organon Teknika, Oss, 
Netherlands. 
 
2.9 Statistical analysis 
     In this study, all data were reported as 
Mean ± SD, and were analyzed and plotted 
by GraphPad Prism, version 8 (GraphPad 
Software, San Diego, CA). Statistical 
analysis was carried out by performing 
analysis of variances (ANOVA) test as 
followed by post hoc Tukey. The 
significance level was considered less than 
5 percent to assess the differences.  
3. Results 
Characterization of Niosomal 
Tmx/Cur Formulations 
     As presented in Table 1, different 
niosomal formulations of Tmx/Cur were 
prepared with the consent of span surfactant 
at two lipid / drug ratios. Based on the 
results (Table 2), each niosomal 
formulations with different lipid to drug 
molar ratio and different surfactant types 
showed various size and polydispersity 
index. Between the various surfactants used, 
span 80 with 10 and 20 lipids to drug molar 
ratios of the desired formulas had 
optimization parameters.  
As shown in Table 2, the best niosomal 
formulation containing two drugs is the TC6 
formulation, since it has the best size and 
dispersion of particles, and also a high rate 
of encapsulation efficiency for both drugs in 
one structure.  
 
Table 2. Vesicle size, PDI, and EE % of different niosomal formulations. Data are represented as mean ± SD, n = 3. 
 
Morphological Characterization of 
Optimized Niosomes 
    Figure 1 shows the optimal niosomal 
formulation that confirms uniform spherical  
morphology and a smooth surface with an 
average length of 80nm without 








Drugs Release Study 
     The study results of the Tmx/Cur release 
profile from the optimum formulation for 
0.5-72 h, at 37 ° C (pH=7.4 and 5) show 
that the cumulative diffusion profile is 




86.2213±1.9238 90.5476±2.7531 0.223±0.033 319.15±6.58 TC1 Tmx/Cur 
(TC) 90.2741±0.7894 94.2103±1.0278 0.169±0.009 190.20±8.63 TC2 
93.7823±1.8852 95.2278±0.6342 0.189±0.028 172.70±3.96 TC3 
90.0250±2.0763 92.2996±1.5021 0.218±0.039 367.00±14.57 TC4 
93.1279±1.4895 96.7421±1.1139 0.208±0.030 286.55±2.47 TC5 
96.3941±2.3383 98.3674±1.1930 0.192±0.001 159.45±10.39 TC6 
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biphasic and decreased for the nano-drugs 
formulation compared to the free drugs 
[10].  
In general, the release data were examined 
with different kinetic models and were 
found to follow the Korsmeyer-Peppas 
model and the drug release was controlled 








Table 3. Different models of kinetic and their parameters for Tmx/Cur release from niosomal formulation at different pH 
Release model Tmx Cur 
First-Order 
 
Tmx (pH 7.4): R
2
=0.7105 Cur (pH 7.4): R
2
=0.9150 
Tmx+ Cur (pH 7.4): R
2
=0.6453 Tmx+ Cur (pH 7.4): R
2
=0.9484 
TC6 (pH 5): R
2
=0.7672 TC6 (pH 5): R
2
=0.6895 
TC6 (pH 7.4): R
2





Tmx (pH 7.4): R
2
=0.8507 Cur (pH 7.4): R
2
=0.9688 
Tmx+ Cur (pH 7.4): R
2
=0.8081 Tmx+ Cur (pH 7.4): R
2
=0.9877 
TC6 (pH 5): R
2
=0.8028 TC6 (pH 5): R
2
=0.9579 
TC6 (pH 7.4): R
2






Tmx (pH 7.4): R
2
=0.8474, n=0.4950 Cur (pH 7.4): R
2
=0.9240, n=0.6113 
Tmx+ Cur (pH 7.4): R
2
=0.8913, n=0.4135 Tmx+ Cur (pH 7.4): R
2
=0.8700, n=0.5980 
TC6 (pH 5): R
2
=0.8942, n=0.5286 TC6 (pH 5): R
2
=0.9737, n=0.4316 
TC6 (pH 7.4): R
2





Physical stability study  
     As shown in Figures 3A and 3B, the size 
and PDI of the niosomal formulation 
containing Tmx/Cur increased with 
increasing storage temperature and storage 
time, whereas the EE (Figure 3C) was less 
sensitive to these parameters. The size 
variations were significant on days 14, 30 
and 60 (p-value <0.05, p-value <0.001 and 
p-value <0.01 respectively) and the PDI for 
TC6 formulation was significant only on 
day 60 (p-value<0.05). In addition, for the 
EE, there was a significant difference 
between the two temperatures studied, only 
for Cur at 30 and 60 days (Figure 3C). 
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Figure 3. The effect of time and temperature of storage on the average size (A), PDI (B), and EE (C) of Tmx /Cur loaded 
niosomal formulation, (* p-value <0.05, ** p-value <0.01, and *** p-value <0.001). 
 
In Vitro Cell Viability  
     Cytotoxicity was evaluated by MTT 
assay for niosome, Tmx, Cur, Tmx+ Cur 
and Tmx/ Cur loaded to niosomes (Nano 
(Tmx+ Cur)) on HEK-293 cell lines and 
MCF-7 cell lines. As can be seen in Figure 
4 B, the encapsulation of drugs by niosomes 
significantly improved drug 
biocompatibility(p-value<0.05), which may 
be due to the low rate of release of drug 
molecules from the niosomal formulation 
into the physiological environment. This is 
consistent with the release data at this pH 
too. The results showed (Figure 4A) that the 
treatment of breast cancer cells (MCF-7) 
with niosomes loaded with Tmx/ Cur had a 
significantly higher inhibitory effect than 
the free drug solution (p-value<0.05) which 
can be attributed to the acidic environment 
of the cancer cells and the release of drugs 
from the niosomes (Figure 2). The synergy 
of Tmx and Cur also results in a stronger 
inhibitory effect (p-value<0.05), with the 
simultaneous loading of the two drugs in the 
niosomal formulation enhancing their 
inhibitory effects on the cancer cells tested 
(Table 4 for IC50 values).  
 
 
Figure 4.  The effect of samples on the viability of A) MCF-7 cells. B) The effect of Tmx + Cur and Nano (Tmx+ Cur) 
on the viability of HEK-293 cells by MTT assay (* p-value <0.05, ** p-value <0.01, and *** p-value <0.001). 
 
 Table 4. The calculated IC50 values for different samples against MCF-7 cell line using MTT assay 
 
IC50(µg/ml) Niosome Tmx  Cur Tmx+ Cur Nano (Tmx+ Cur) 
565.35±2.58 41.98±2.33 63.12±7.31 36.16±1.99 20.68±1.25 
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4. Discussion 
     In the present study, effect of some 
parameters such as surfactant type, and lipid 
to drug ratio on size, PDI and entrapment 
efficiency of niosomal formulations were 
assessed. The results showed that the size of 
niosomal formulations synthesized with 
span 20 and 60 using lipid to drug 10 ratio 
was significantly smaller than formulations 
with lipid/drug ratio of 20. Also, in the case 
of niosomal formulations with span 80, 
nanoparticles prepared with lipid to drug 
ratio of 20 showed smaller size than lipid to 
drug ratio of 10. This process can be 
attributed to the hydrophobic chain length 
of the Span structure, which increases from 
Span 20 to Span 80 and the greater 
hydrophobic-hydrophobic interaction 
between encapsulated Tmx/Cur, cholesterol 
and the surfactant hydrophobic chain [11].  
Also, according to the results, the 
encapsulation efficiency of Tmx and Cur is 
reliant on the size of the niosome and can be 
the result of hydrophobic-lipophilic balance 
(HLB) which is the ratio of hydrophobic to 
the hydrophilic portion of surfactant and 
depends on the type and amount of the 
surfactant [11, 12].  
Results of the drug release from niosomal 
formulation showed that the cumulative 
diffusion profile is biphasic and decreased 
for the nano-drugs formulation compared to 
the free drugs [10]. The first stage of rapid 
release may be due to the desorption of 
drugs from the outer surface of the 
niosomes, and the lower rate of release 
often relates to drug release through the two 
layers [13]. Significant release of both drugs 
can be seen by decreasing the pH of the 
environment[14]. The reason for this trend 
may be due to swelling and breakage of 
niosomes in acidic situations, which is a 
common behavior in niosomes. PH-
Dependent release of drugs is often suitable 
for the treatment of cancers because the 
environment around the cancer cells is 
acidic while it is not so in healthy cells. The 
drug release was controlled by diffusion and 
erosion mechanism. N values calculated at 
each pH (0.43 <n <0.85) indicate 
anomalous transport mechanism for drug 
release[15].  
Based on the data obtained from stability 
test, the niosomal formulations can be 
maintained for at least two weeks with 
minimal change in size and content of the 
drug; however, for the samples stored at 4 
°C compared to 25 °C are lower and slower, 
it might be due to less mobility of bilayer at 
4°C [16]. However, experiments typically 
show an increase in the size of vesicles 
during storage due to their fusion [17] or 
aggregation [18].  
The IC50 content of the nanocarrier 
containing 20.68 μg/ml decreased 
significantly compared to the combination 
of the two drugs (36.16 μg/ml) and the drug 
solution (41.98 and 63.12 μg/ml for Tmx 
and Cur, respectively  ( (P-value <0.05). In 
conclusion, it appears that encapsulation of 
Tmx/Cur by niosomes (TC6) increases anti-
proliferative activity[19].  Also, IC50 of 
niosome (about 570 μg/ml) indicates that 
the niosomes not only have a low toxicity to 
cancer cells but at high concentrations, they 
do not have toxic effects on the MCF-7 cell 
line [20, 21].  
In a 2015 study by Roghayeh Abbasali 
Porkhir et al., apoptosis induced by Tmx 
and Tmx loaded on solid lipid nanoparticles 
(SLN) was determined on MCF-7 and 
MDA-MB231 breast cancer cells and the 
results showed that Tmx loaded with SLN 
had a cytotoxic effect on MCF-7 and MDA-
MB231 cells compared to free Tmx[22]. 
 
5. Conclusion 
     Optimal formulations of niosomes 
containing two drugs were prepared by 
varying the surfactant type (span 20, 60 and 
span 80) and lipid-to-drug ratio and finally 
selected according to the size and 
encapsulation efficiency (span 80 and lipid 
to drug molar ratio of 10). Optimum 
formulations had a controlled release at 
physiological pH while burst release at 
acidic pH was observed. This property helps 
niosomal carriers to be more effective in the 
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acidic environment of breast cancer cells 
than normal cells. Also, the while niosomes 
carrying Tmx and Cur have good 
biocompatibility with HEK-293 normal 
cells, they show significant toxicity in 
MCF-7 breast cancer cells. Finally, the data 
from this study may provide one possible 
way to optimally treat breast cancer. 
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